EGFR and lung adenocarcinoma: In the past, the treatment options for advanced or metastatic disease were typically confined to chemotherapy or radiation therapy, but the advent of targeted therapies as EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase) inhibitors have led to improved outcome in some patients who harbor driver oncogenes, especially in lung adenocarcinomas [4,5].